Open Access<p>Molecular Requirements for the Expression of Antiplatelet Effects by Synthetic Structural Optimized Analogues of the Anticancer Drugs Imatinib and Nilotinib</p>
Author(s) -
Despoina Pantazi,
Nikoleta Ntemou,
Alexios Brentas,
Dimitrios Alivertis,
Konstantinos Skobridis,
Alexandros D. Tselepis
Publication year - 2019
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s211907
Subject(s) - nilotinib , imatinib , tyrosine kinase , pharmacology , chemistry , tyrosine kinase inhibitor , ic50 , cancer research , medicine , biochemistry , in vitro , receptor , cancer , myeloid leukemia
Platelets play important roles in cancer progression and metastasis, as well as in cancer-associated thrombosis (CAT). Tyrosine kinases are implicated in several intracellular signaling pathways involved in tumor biology, thus tyrosine kinase inhibitors (TKIs) represent an important class of anticancer drugs, based on the concept of targeted therapy.